id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-1656-0005,FDA,FDA-2013-E-1656,"Determination of Regulatory Review Period for Purposes of Patent 
Extension; XELJANZ",Notice,Determinations,2015-06-12T04:00:00Z,2015,6,2015-06-12T04:00:00Z,2015-12-10T04:59:59Z,2016-01-12T19:18:52Z,2015-14433,0,0,0900006481b30329
FDA-2013-E-1656-0004,FDA,FDA-2013-E-1656,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-03-31T04:00:00Z,2015,3,2015-03-31T04:00:00Z,,2015-03-31T18:44:07Z,,0,0,0900006481a7e840